Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Virtual Model of Novel Cancer Target DevelopedPlebiotic and Pharmacellion Complete Research Project on an in silico Molecular Modelling and Molecular Dynamics Model of Na K ATPase
By: Pharmacellion Ltd The sodium-potassium pump, Na K ATPase, is an important enzyme located in the membrane of animal cells. This enzyme is responsible for the active transport of sodium and potassium ions through the cellular membrane. This ion pump is also involved in the development and progression of some types of cancer, so it is an interesting target for cancer therapeutics. Pharmacellion has designed several compounds as inhibitors of Na K ATPase, with increased affinity with the ion pump and having modifications - relative to other known inhibitors - that are intended to reduce possible side effects. Using Plebiotic methods, a 3D computer model of the target protein was generated and various gaps in the model were filled using specialised software. 3D structures of six Pharmacellion compounds were then generated and refined using various software tools, before being used in docking simulations with the target model. All six Pharmacellion compounds were found to dock with their target. The model of Na K ATPase was then inserted into a virtual cell membrane model with the necessary water molecules and sodium, potassium and chloride ions needed for predicting the affinity of the compounds for the target using Plebiotic’s rapid Molecular Dynamics platform, PleMD. The Molecular Dynamics results from this virtual model demonstrated good binding and affinity for all six Pharmacellion compounds studied, with lead compounds PCLN-202 and PCLN-201 having the highest affinity. “We are very pleased with the results of this study, which confirm not only the promising characteristics of Pharmacellion’ Álvaro López Medrano, CEO of Plebiotic noted, “It has been a really interesting project considering this large and complex nature of the target protein. We are happy to see that the simulations produced by the PleMD platform have confirmed high affinity binding of the Pharmacellion compounds, as predicted by conventional studies.” End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|